2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

immunogenic cell death (ICD)

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99683
    Ladiratuzumab vedotin

    SGN-LIV1A

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
    Ladiratuzumab vedotin
  • HY-163099
    P5(PEG24)-VC-PAB-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Apoptosis Cancer
    P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
    P5(PEG24)-VC-PAB-Exatecan
  • HY-170884
    ICD inducer-1

    		ER-phagy Cancer
    ICD inducer-1 (Compound Re1) is an effective immunogenic cell death (ICD) inducer that can target the endoplasmic reticulum (ER) and block ER-phagy at the late stages. ICD inducer-1 is promising for research of cancers .
    ICD inducer-1
  • HY-142956
    ROS-ERS inducer 1

    		Reactive Oxygen Species (ROS) Cancer
    ROS-ERS inducer 1 is a type II ICD (immunogenic cell death) inducer. ROS-ERS inducer 1 is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. ROS-ERS inducer 1 successfully induces endoplasmic reticulum stress (ERS) accompanied by reactive oxygen species (ROS) generation and finally lead to the release of damage-associated molecular patterns (DAMPs) in HCC cells. ROS-ERS inducer 1 displays much higher anticancer activities than Cisplatin .
    ROS-ERS inducer 1
  • HY-149631
    HFY-4A

    		HDAC Cancer
    HFY-4A is a HDAC inhibitor. HFY-4A inhibits breast cancer cell proliferation, migration, and invasion, and induces cell apoptosis. HFY-4A induces immunogenic cell death (ICD). HFY-4A inhibits tumor growth in breast cancer xenograft mouse models .
    HFY-4A
  • HY-161693
    Telomeric G4s ligand 1

    		G-quadruplex DNA/RNA Synthesis Apoptosis Cancer
    Telomeric G4s ligand 1 is a telomeric G-quadruplex ligand that stabilizes telomeric G4 and induces R-loop formation, leading to DNA damage responses. Telomeric G4s ligand 1 induces apoptosis and evokes immunogenic cell death (ICD) in tumor cells .
    Telomeric G4s ligand 1
  • HY-158775
    Ferroptocide

    		Ferroptosis Apoptosis Autophagy Cancer
    Ferroptocide is a cell death inducer that triggers ferroptosis and has anti-tumor activity. Ferroptocide can induce oxidative stress, leading to G2/M cell cycle arrest and apoptosis activation in LNCaP cells, while also effectively inhibiting the cell viability of both LNCaP and TRAMP-C1 cells. Ferroptocide can be used to study its capability to induce mitochondrial autophagy and to trigger immunogenic cell death (ICD) in prostate cancer cells .
    Ferroptocide
  • HY-169957
    ROS-ERS inducer 2

    		Reactive Oxygen Species (ROS) Cancer
    ROS-ERS inducer 2 (Complex 3f) triggers intracellular ROS generation and affect the function of mitochondria. promote the release of damage-associated molecular patterns (DAMPs), induce immunogenic cell death (ICD) and activates endoplasmic reticulum stress (ERS). ROS-ERS inducer 2 plays an important role in anti-liver cancer research .
    ROS-ERS inducer 2
  • HY-173023
    IDOi-Pt(IV) prodrug-1

    		Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species (ROS) Cancer
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .
    IDOi-Pt(IV) prodrug-1
  • HY-175048
    Pt(II)-NHC complex 2C

    Platinum(II)-N-heterocyclic carbene complex 2C

    		 Reactive Oxygen Species (ROS) Apoptosis ER-phagy Cancer
    Pt(II)-NHC Complex 2C (Platinum(II)-N-Heterocyclic Carbene complex 2C) (Compound 2C) is a platinum(II) complex based on N-heterocyclic carbene (NHC). Pt(II)-NHC Complex 2C is an immunogenic cell death (ICD) inducer that can induce endoplasmic reticulum stress (ERS) in liver cancer cells and produce reactive oxygen species (ROS), ultimately leading to the release of damage-associated molecular patterns (DAMP). Pt(II)-NHC Complex 2C blocks the cell cycle at the S phase and significantly induces cell apoptosis. Pt(II)-NHC Complex 2C shows anti-liver cancer potential in mouse models and activates immune cells in liver injury models.
    Pt(II)-NHC complex 2C
  • HY-181673
    ICD inducer-2

    		Microtubule/Tubulin Apoptosis Bcl-2 Family Caspase PARP Cancer
    ICD inducer-2 is a immunogenic cell death inducer. ICD inducer-2 binds to the colchicine binding site on tubulin to inhibit tubulin polymerization. ICD inducer-2 exhibits broad-spectrum antiproliferative activity across multiple cancer cell lines. ICD inducer-2 inhibits cells migration, causes G2/M phase and induces apoptosis. ICD inducer-2 promotes infiltration of CD4+ and CD8+ T cells into the tumor microenvironment. ICD inducer-2 downregulates antiapoptotic protein Bcl-2, upregulates proapoptotic proteins Bax and Bim-1, and increases cleaved caspase 3, cleaved caspase 9, and cleaved PARP levels. ICD inducer-2 overcomes paclitaxel resistance in xenograft models and achieves tumor growth inhibition. ICD inducer-2 can be used for the research of cancer, such as lung carcinoma .
    ICD inducer-2
  • HY-181005
    FGFR-IN-25

    		FGFR Akt PERK Reactive Oxygen Species (ROS) Caspase Pyroptosis PD-1/PD-L1 Neurological Disease Cancer
    FGFR-IN-25 (Compound 19E) is a FGFR inhibitor (IC50s: 1.30 nM and 0.85 nM for FGFR1 and FGFR2, respectively) and radiosensitizer. FGFR-IN-25 effectively reduces the phosphorylation of FGFR1 and its key downstream effectors, pAKT and pERK. FGFR-IN-25 exerts broad-spectrum antitumor activity against gastric cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, triple-negative breast cancer, and glioblastoma. FGFR-IN-25, when combined with radiotherapy, synergistically activates the ROS-Caspase-3-GSDME axis, downregulates PD-L1 expression, and induces immunogenic cell death (ICD). FGFR-IN-25 combined with radiotherapy improves the antitumor efficacy .
    FGFR-IN-25
  • HY-180245
    STAT3-IN-51

    		STAT Ferroptosis Apoptosis Glutathione Peroxidase Bcl-2 Family Reactive Oxygen Species (ROS) Cancer
    STAT3-IN-51 is a STAT3 inhibitor that directly binds to the STAT3 SH2 domain. STAT3-IN-51 induces apoptosis, ferroptosis, and immunogenic cell death (ICD) to potentiate anti-tumor immunity. STAT3-IN-51 inhibits STAT3 activation (phosphorylation, p-STAT3) and its downstream signaling. STAT3-IN-51 induces ROS generation, decreases Bcl-2 expression, disruptes mitochondrial function, suppresses GPX4 activity, and promotes lipid peroxidation. STAT3-IN-51 can be used for the study of colorectal carcinoma, breast adenocarcinoma, non-small cell lung cancer (NSCLC) and Cisplatin (HY-17394)-resistant pulmonary adenocarcinoma .
    STAT3-IN-51

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: